Glycopeptide Antibiotics Market: Analysis, Trends & Forecast 2024-2033 | Growth, Size & Share Insights

The glycopeptide antibiotics market size has grown strongly in recent years. It will grow from $3.31 billion in 2023 to $3.58 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increasing antibiotic resistance, rising incidence of infectious diseases, government initiatives, increasing healthcare expenditure, globalization of infectious diseases.

The glycopeptide antibiotics market size is expected to see strong growth in the next few years. It will grow to $5.02 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to emerging infectious diseases, increasing geriatric population, continued antibiotic resistance challenges, r&d investments and innovations, expansion of healthcare infrastructure. Major trends in the forecast period include increasing antibiotic resistance, advancements in research and development, global health emergencies driving demand, collaborations for antibiotic stewardship, market expansion in emerging economies.

Market Overview -
Glycopeptide antibiotics are a group of antibiotics having structures that either comprise a glycosylated cyclic or polycyclic non-ribosomal peptide, used to inhibit bacterial cell wall formation. They were first discovered from plant and soil bacteria.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=9444&type=smp

The Surging Demand For Glycopeptide Antibiotics In The Face Of Rising Cancer And Infectious Disease Cases
The rising number of cancer and infectious disease cases is expected to propel the growth of the glycopeptide antibiotics market going forward. Cancer refers to a disease that occurs when certain body cells multiply beyond their limits and spread to other body regions, whereas, infectious diseases are disorders produced by organisms such as bacteria, viruses, fungus, or parasites. The glycopeptide antibiotics are used to treat a variety of infectious disorders caused by methicillin-resistant staphylococcus aureus, streptococcus, or enterococcus bacteria that are resistant to beta-lactams and other antibiotics. In cancer patients, glycopeptide antibiotics are used to boost radiotherapy's antitumor effects by eliminating not only the targeted cancer cells but also distant cancer cells farther in the body. For instance, according to the American Cancer Society, a US-based non-profit health organization committed to cancer eradication, in 2022, the US had 1.9 million new cancer cases and 609,360 cancer deaths, for a total of 1,670 fatalities each day. Therefore, the rising cancer and infectious disease cases will drive the growth of the glycopeptide antibiotics market.

Competitive Landscape -
Major companies operating in the glycopeptide antibiotics market report are ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Mylan N.V., Novartis AG, Hikma Pharmaceuticals Plc., Aurobindo Pharma Limited, Abbvie Inc., Melinta Therapeutics Inc., Cumberland Pharmaceuticals Inc., Theravance Biopharma Inc., Janssen Global, Bristol-Myers Squibb Company, GSK Plc., Allergan Plc., Shenwei Pharmaceutical Hainan Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Lytix Biopharma, Alvogen, Eli Lilly and Company, Bayer AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Sanofi SA, Targanta Therapeutics, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Inc. .

Leiden University's Breakthrough Discovery Of Enhanced Vancomycin Variants Marks A Milestone In Glycopeptide Innovation
Product innovation is a key trend gaining popularity in the glycopeptide antibiotics market. Major companies operating in the glycopeptide antibiotics market are focused on developing innovative products to strengthen their position in the market. For instance, In October 2022, Leiden University, a Netherlands-based research university, discovered new variants of the antibiotic vancomycin. A group of molecules was attached to the structure of an existing vancomycin molecule to create the new variant antibiotic vancomycin. The new variant of vancomycin is up to a thousand times more active against gram-positive bacteria than the original vancomycin and has lower nephrotoxicity when compared to commercially utilized polymyxin antibiotics. This was created to solve the problem since vancomycin can only be effective against gram-positive strains and it cannot pass through the outer membrane (OM) of gram-negative bacteria.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report

Key Segments -
The glycopeptide antibiotics market covered in this report is segmented -
1) By Drug: Vancomycin, Dalbavancin, Oritavancin, Other Drugs
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By Indication: Skin And Structure Infection, Meningitis, Clostridioides Difficile Infection, Enterocolitis, Other Indications
4) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.